British Columbia-based Chinook Therapeutics burst onto the scene with $65 million in hand and a goal of driving a portfolio of compounds aimed at kidney diseases into the clinic by 2021.
The Canadian government announced final regulations to reduce patented drug prices expected to save Canadians C$13.2 billion over a decade, overriding heavy pharma company opposition.
Canada’s main pharmaceutical lobby group urged the government not to wait for drug shortages before responding to U.S. plans to import Canadian drugs, according to documents seen by Reuters.
The Trump administration took a step toward allowing the importation of medicines from Canada, an action the president has advocated as a way to bring cheaper Rx drugs to Americans.
Canada opposes any U.S. plans to buy Canadian prescription drugs that might threaten the country’s drug supply or raise costs for its own citizens – officials told U.S. authorities – in a new setback to the Trump administration’s efforts to tackle high drug prices, according to documents obtained by Reuters.
A Canadian advisory council studying prescription drug coverage said the federal government should create a universal, single-payer public pharmacare system, and warned that the current framework requires significant reforms.
The Canadian government has assured the pharmaceutical industry that new features of its plan to cut drug costs would apply only to new medicines, Health Canada said, offering some relief to drugmakers even as other regulations could still lower prices of medicines already on the market.
The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.
Through consultation with physicians and patients, the Canadian Breast Cancer Network (CBCN) outlined five key recommendations for consideration when implementing biosimilars in oncology
The U.S. FDA approved AbbVie Inc.’s Skyrizi as a treatment for plaque psoriasis at a time when the company’s blockbuster psoriasis medicine Humira faces patent pressures.